From: BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors
Cell Line
Venurafenib
Afatinib
Panitumumab
Venurafenib+. Panitumumab
Venurafenib+ Afatinib
SW-48
–
+ (L)
- +
Colo-205
+
+ +
+ + (L)
HT29
+ (H)
+ −
+ + (H)